This observational analysis assessed whether receipt of adjuvant radiotherapy (RT) after breast-conserving surgery is associated with breast cancer–specific survival (BCSS) among patients with early-stage node-negative luminal (HR+/HER2-) breast cancer, and whether that association differs by the primary tumor quadrant location.
The analysis used population-level data to evaluate survival associations and to generate hypotheses about quadrant-specific effects of postoperative RT.
The cohort comprised 5,831 patients with T1-2N0M0 luminal (HR+/HER2-) breast cancer who underwent breast-conserving surgery, identified from the Surveillance, Epidemiology, and End Results (SEER) database for the years 2010–2017. Patients were stratified based on whether they received postoperative RT.
No additional patient-level details (for example, receipt of systemic endocrine therapy, margin status, or comorbidities) were reported in the abstract; such details are not available from the source text provided here.
The investigators analyzed BCSS using several complementary methods:
The study also reported sensitivity analyses including Fine–Gray modeling and calculation of E-values to assess robustness to unmeasured confounding.
In adjusted Cox regression, receipt of RT after breast-conserving surgery was independently associated with a lower hazard of breast cancer–specific death: hazard ratio (HR) = 0.623 (95% confidence interval [CI], 0.512–0.792; P < 0.001).
Analysis with the Fine–Gray competing-risk model produced a consistent finding: the subdistribution hazard ratio for RT was 0.661 (95% CI, 0.530–0.825; P < 0.001), indicating a lower cumulative incidence of breast cancer–specific death after accounting for competing events.
A statistically significant interaction between RT and primary tumor quadrant location was observed (interaction P = 0.019). This indicates that the magnitude—or statistical significance—of the association between postoperative RT and BCSS varied depending on the quadrant in which the primary tumor resided.
When analyses were stratified by tumor quadrant, the adjusted association between RT and reduced hazard of breast cancer–specific death reached statistical significance for tumors located in the upper-inner and lower-outer quadrants. For tumors in the upper-outer and lower-inner quadrants, the point estimates were reported to be in the same (protective) direction but did not achieve statistical significance in the abstract.
The abstract does not provide the quadrant-specific numerical hazard ratios, confidence intervals, or P values; these details were not reported in the source text provided here.
The authors report sensitivity analyses using the Fine–Gray competing-risk model and E-value calculations that were consistent with the primary findings. These analyses were intended to evaluate robustness of the observed association to competing risks and to potential unmeasured confounding.
Specific E-value magnitudes or additional modeling parameters were not reported in the abstract and therefore are not available from the source text provided here.
This is an observational, registry-based analysis using SEER data. As such, the findings are subject to confounding by indication and limitations inherent to retrospective registry research, including potential lack of detailed clinical covariates in the public abstract. The authors explicitly state that the quadrant-dependent association between RT and BCSS constitutes a hypothesis that requires prospective validation before it can inform individualized treatment decisions.
The study supports an association between adjuvant postoperative radiotherapy and improved breast cancer–specific survival in T1-2N0M0 luminal (HR+/HER2-) breast cancer at the population level, consistent across Cox and competing-risk analyses. The observation of a significant RT-by-quadrant interaction raises the hypothesis that the survival benefit associated with RT may vary by primary tumor location within the breast.
Given the retrospective design and the need for prospective confirmation, these results should be viewed as hypothesis-generating rather than practice-changing. Prospective studies or randomized data would be required to validate quadrant-specific differences and to justify modification of standard adjuvant RT recommendations based on tumor quadrant location.